INTRODUCTION
Modulation of host immune responses is a common strategy for promoting virus persistence and avoiding clearance. Human cytomegalovirus (HCMV) encodes numerous immunomodulatory genes, including a homologue of the cytokine human interleukin-10 (hIL-10) (Finlay & McFadden, 2006; Lehner & Wilkinson, 2001; Slobedman et al., 2009) . While having limited sequence similarity to hIL-10, cytomegalovirus (CMV) IL-10 (cmvIL-10) has been reported to share many functional characteristics with hIL-10 (Spencer et al., 2002) .
About 60 % of the population of Western societies are infected with CMV and more than 90 % of the world population are infected with Epstein-Barr virus (EBV) (Bego & St Jeor, 2006; Salek-Ardakani et al., 2002) . In immune-competent individuals, both CMV and EBV infections cause asymptomatic and lifelong latent infections (Hislop et al., 2007; Kano & Shiohara, 2000) , and the viruses may cause severe morbidity and mortality in immune-compromised individuals (Cheung & Teich, 1999; Drew, 1988; Griffiths & Walter, 2005; Kano & Shiohara, 2000; Rowshani et al., 2005; Vancíkova & Dvorák, 2001 ). Both viruses encode viral IL-10 ( Kotenko et al., 2000; Lockridge et al., 2000; Moore et al., 1990) . Hence, the immune system is likely to be introduced to viral IL-10 homologues, which, as non-self molecules, might trigger the production of antibodies. These antibodies could eventually cross-react with human IL-10, thereby behaving as anti-IL-10 autoantibodies (de Lemos Rieper et al., 2009a) . transcription of pro-inflammatory cytokines and downregulation of the expression of co-stimulatory proteins and MHC class I and II molecules (Couper et al., 2008; de Waal Malefyt et al., 1991; Spencer et al., 2002) . These effects are almost certainly mediated by human IL-10 receptors. This is supported by the fact that downregulation of proinflammatory cytokines involves the JAK-STAT signalling pathway and the transcription of genes encoding suppressor of cytokine signalling-3 (SOCS3) (Couper et al., 2008; Moore et al., 2001) .
The purpose of this study was to confirm that the bioactivity of human cmvIL-10 on human cells occurs via IL-10 receptors, and to examine to what extent HCMV-infected individuals produce antibodies against cmvIL-10. We observed that 28 % of healthy human CMV-seropositive blood donors produced high avidity and in vitro-neutralizing antibodies against cmvIL-10. The antibodies bound selectively to cmvIL-10 and displayed no cross-reactivity with either ebvIL-10 or hIL-10. The overall methodology that was used in this study was based on a gentle radioiodine labelling of cmvIL-10 and a thorough validation of the tracer.
RESULTS

Validation of 125 I-cmvIL-10
Measurement and characterization of cytokine antibodies requires sensitive, robust and reliable methodology. It is our experience from multiple studies in this regard that radioimmunoassay (RIA) is the most appropriate methodology. Our RIA approaches have been based on radioiodination of recombinant cytokines (de Lemos Rieper et al., 2009a) . In this context it is vital that both the source material, i.e. the recombinant cytokine, and the radioiodinated cytokine are properly validated to endorse subsequent measurements as being compelling and biologically understandable. Basically, it has to be assured that the source material has retained bioactivity, and after the iodination procedures it has to be assured that the labelled cytokine has retained its three-dimensional conformation, i.e. as judged by its ability to bind to specific antibodies and/or cellular receptors (de Lemos Rieper et al., 2009b) . The preparation of cmvIL-10, which is the basis of the methodology of this paper, was validated as follows: Fig. 1(a) shows that cmvIL-10 was equally as bioactive as hIL-10, as judged by the inhibition of LPS-induced IL-1b from blood mononuclear cells. Previously, we iodinated and thoroughly validated the biochemical properties of recombinant hIL-10. The hIL-10 tracer was a dimeric protein that bound with high avidity to IL-10R complexes on blood mononuclear cells (de Lemos Rieper et al., 2009b) . It is clear from Fig. 1(b) that 125 I-labelled cmvIL-10 had a molecular mass comparable to 125 I-labelled hIL-10 (~36 kDa), and the tracer eluted correctly as a homodimer compared to 125 I-labelled hIL-6 (~20 kDa). More than 90 % of the cmvIL-10 tracer bound specifically to goat anti-cmvIL-10 antibodies (Fig. 1b) . Furthermore, 125 Ilabelled cmvIL-10 bound saturably to blood mononuclear cells with an avidity (K d 520 pM) (Fig. 2a) I-labelled cmvIL-10 blood mononuclear cell-binding activity was displaced by unlabelled cmvIL-10 as well as hIL-10 (Fig. 2b) , confirming that cmvIL-10 bound to the same receptors as hIL-10. The binding activity was also inhibited by anti-cmvIL-10 (Fig. 2b) .
Screening of blood donors for antibodies directed against cmvIL-10
Having ensured that the cmvIL-10 tracer was biochemically intact and biologically representative, we carried on with measurements of putative anti-cmvIL10 antibodies in normal blood donors. The principle of these antibody measurements relies on the demonstration that cmvIL-10 molecules bind substantially and in a saturable manner to antibodies present in plasma. After incubating cmvIL-10 tracer in plasma samples, antibody binding is visualized by chromatographic techniques and/or antibody precipitations. Screening of 33 plasma pools (each consisting of 96 individual plasmas derived from normal blood donors) demonstrated that 26 of them contained measurable amounts of anti-cmvIL-10 antibodies (Fig. 3a) that bound specifically to 125 I-labelled cmvIL-10 (Fig. 3b) .
Human anti-cmvIL-10 antibodies bind cmvIL-10 specifically and are predominantly of the IgG class Despite the fact that hIL-10 could displace the binding of cmvIL-10 to blood mononuclear cells (Fig. 2b) , there was no measurable anti-cmvIL-10 antibody cross-reactivity with either hIL-10 or ebvIL-10 (Fig. 3b) . Hence, anticmvIL-10 antibodies bound exclusively to cmvIL-10. A comparison of binding data from two plasma pools consisting of six individual anti-cmvIL-10 antibodypositive or -negative plasmas revealed polyclonal IgG molecules to be the predominant cmvIL-10-binding plasma factors. The plasma pools were incubated with 125 I-labelled cmvIL-10 and then subjected to Sephadex G-75 superfine molecular size chromatography (PD75) (to assess total plasma cmvIL-10 binding activity), affinity chromatography on protein-G (to assess cmvIL-10-IgG binding activity) and precipitation with specific rabbit antibodies against either human Fab (assessing the cmvIL-10 binding activity of all immunoglobulin molecules carrying k and/or l chains) or human Fc gamma (to assess cmvIL-10-IgG binding activity). Since both anti-k and anti-l antibodies precipitated substantial amounts of cmvIL-10 in the anti-cmvIL-10 antibody-positive pool only, we conclude that the antibody response was polyclonally derived. The observation that the total cmvIL-10 plasma binding (PD75) corresponded to the binding attributable to IgG (assessed by protein-G chromatography and precipitation with anti-IgG as well as anti-k and/or l antibodies) supported the notion that the predominant cmvIL-10 binding activity of plasma was attributable to IgG carrying both k and l light chains (Fig.  4a) . Immunoglobulin precipitation experiments in four individual plasmas from CMV-seropositive blood donors confirmed that anti-cmvIL-10 antibodies were predominantly polyclonally derived IgG (Fig. 4b-e ).
An examination of 477 individual blood-donor plasmas showed an overall seroprevalence of anti-cmvIL-10 IgG of 16.8 % (Table 1) , and 4.4 % of blood donors in general produced a high titre of antibodies (Table 1 and Fig. 5a ). We observed that 60 % of the blood donors were infected with CMV (n550), as assessed by detecting measurable amounts of anti-CMV-IgG (data not shown). Thus, the overall seroprevalence of anti-cmvIL-10 IgG corresponded to 28 % of the CMV-seropositive blood donors. The antibodies bound cmvIL-10 with the same high avidity as the blood mononuclear cells and were present at nanomolar concentrations (Fig. 5b) . Analogous measurements in plasma from donors 4 and 5 gave similar results (donor 4, K d 520 pM and B max 52778 pM; donor 5, K d 515 pM and B max 51078 pM).
With the exception of one plasma sample (from a seroconverting donor), anti-cmvIL-10 antibodies were only detectable in CMV-seropositive plasma samples. No correlation was observed between anti-cmvIL-10 antibodies and antibody reactivity in the anti-CMV antibody test.
Human anti-cmvIL-10 IgG antibodies neutralize cmvIL-10 in vitro Anti-cmvIL-10 antibodies substantially inhibited the blood mononuclear cell binding of cmvIL-10 (Fig. 6a) . Furthermore, anti-cmvIL-10 antibodies strongly, and in a saturable manner, neutralized the suppressive function of cmvIL-10 on LPS-induced IL-1b and tumour necrosis factor alpha (TNF-a) from blood mononuclear cells (Fig. 6b) , by inhibiting the cmvIL-10-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) (Fig. 6c) . The bioactivity of lower concentrations of cmvIL-10 was almost totally abrogated, whereas a breakthrough was observed for higher concentrations of cmvIL-10 (i.e. .50 ng ml
21
; Fig. 6b ).
cmvIL-10 might stimulate autocrine production of hIL-10 (Spencer et al., 2008) . To exclude interference from an enhanced production of hIL-10 in the bioassay depicted in ) from R&D Systems and stimulated with LPS for 8 h at 37 6C. The supernatant levels of IL-1b were measured by ELISA. The experiment was performed in triplicate. The relative concentrations of IL-1b (100 % corresponds to 1400 ng ml "1 ) are shown with the mean and SD calculated from three separate experiments. The IL-10-induced differences from LPS-stimulated cells were statistically significant (P,0.05 MannWhitney U test). (b) 125 I-labelled cmvIL-10 and hIL-10 were separated by size chromatography twice. Of the protein added to the column 97 % corresponded to 125 I-labelled cmvIL-10 and hIL-10. Illustrated here are: (i) the secondary separation, demonstrating that both 125 I-labelled cmvIL-10 and hIL-10 eluted as a homodimeric protein with a molecular mass of approximately 36 kDa, (ii) 125 I-labelled rhIL-6 known to be eluted as a 20.3 kDa protein (Hansen et al., 1995) , (iii) 125 I-labelled cmvIL-10 complexed with goat anti-cmvIL-10 antibodies eluted as a high molecular mass complex distinguishable from free 125 I-labelled cmvIL-10 and (iv) isotype control antibodies, which did not bind 125 I-labelled cmvIL-10.
Anti-cmvIL-10 antibodies ), we confirmed that the levels of endogenous human IL-10 in the culture supernatants was ,0.1 ng ml 21 (data not shown). Moreover, no difference was observed in plasma IL-10 levels between blood donors who were positive or negative for anti-cmvIL-10 antibodies (Fig. 7) .
DISCUSSION
Similarly to other viruses, CMV has evolved a multitude of strategies to avoid host immune surveillance and defence. CMV encodes a viral tumour necrosis factor receptor homologue, a potent IL-8-like chemokine and cmvIL-10, the viral homologue of IL-10 (Finlay & McFadden, 2006; Lehner & Wilkinson, 2001; Kotenko et al., 2000) .
We confirmed that cmvIL-10 binds to and activates IL-10 receptors on human cells and is equally as bio-potent as human IL-10. Additionally, we observed that 28 % of healthy CMV-seropositive blood donors produce substantial levels of specific and neutralizing IgG antibodies against cmvIL-10. This suggests that cmvIL-10 is being or has been produced in vivo and secreted at levels that are immunogenic, and that about one-third of the CMV-infected individuals are able to raise a significant humoral immune response against cmvIL-10. In addition, these observations suggest that cmvIL-10 plays an active role in the pathogenesis of CMV infection and that specific antibodies are induced to counteract cmvIL-10 activity in vivo.
Immunity to CMV infection serves to control primary infection and subsequent CMV reactivation (Sinclair, 2008; Vancíkova & Dvorák, 2001) . HCMV triggers responses from many parts of the immune system, and cell-mediated immune responses are likely to represent the predominant mechanisms by which CMV replication is controlled (Vancíkova & Dvorák, 2001 ). There is evidence, however, that antibodies also contribute substantially to protection against and control of CMV (Crough & Khanna, 2009 ). 6 PBMC ml "1 overnight at 4 6C in the presence of a 10 % plasma pool that was negative for anti-cmvIL-10 antibodies, with or without a 500-fold molar excess of either cmvIL-10, hIL-10, 1 : 50 dilution of polyclonal goat anti-cmvIL-10 or 1 : 50 dilution of the corresponding isotype control. Binding was assessed by centrifugation (cell pellet contained cell bound tracer and supernatant contained free tracer). The experiment was performed in triplicate. The relative binding of cmvIL-10 tracer to the IL-10 receptors are shown with the means and SD calculated from the triplicates (100 % corresponds to 3000 c.p.m.). Significant differences were determined using the Mann-Whitney U test.
Passive administration of CMV antibodies offers protection against clinical CMV disease in newborns, which could result from the transfusion of CMV-containing blood. Moreover, administration of CMV antibodies significantly lowers the risk of congenital CMV infection and disease in pregnant women (Nigro et al., 2005) . In the transplant setting, the importance of the humoral response is supported by the fact that CMV infection is more frequent and severe in seronegative solid-organ transplant recipients of a CMV-positive organ (Limaye et al., 2002) . Furthermore, administration of anti-CMV antibodies to renal-and liver-transplant recipients reduces the incidence of CMVassociated syndromes, bacterial or fungal superinfection and graft loss (Falagas et al., 1997; Snydman et al., 1987) . We have studies in progress to assess a possible clinical significance of the anti-cmvIL-10 immune response.
Today, different cmvIL-10 homologues have been identified (Jenkins et al., 2004; Lin et al., 2008) , including the latency-associated cmvIL-10 homologue (LAcmvIL-10) (Jenkins et al., 2004) . Interestingly, LAcmvIL-10 homologue is among the few viral proteins produced during the latent phase of CMV infection. Jenkins et al. (2008) demonstrated that commercial antibodies against cmvIL-10 used in Western blotting also bind to LAcmvIL-10 (Jenkins et al., 2008) . Thus, the antibodies against cmvIL-10 described here might also bind to LAcmvIL-10. In fact, we cannot rule out the antibodies being triggered by and directed against LAcmvIL-10. Unfortunately, LAcmvIL-10 is not commercially available, so we were not able to elaborate on this hypothesis.
Recently, we proposed the theory that individuals producing autoantibodies against cytokines do so as a result of exposure to foreign cytokine-like molecules, as exemplified by viral homologues of cytokines. It is plausible that these non-self cytokine-like molecules could induce antibodies with cross-reactivity against their natural human-cytokine counterpart. Approximately 1 % of apparently healthy blood donors generate autoantibodies against IL-10. Considering viral IL-10 homologues and the induction of IL-10 autoantibodies (de Lemos Rieper et al., 2009b , 2010 , this study rules out the few blood donors producing IL-10 autoantibodies doing this by producing cross-reacting cmvIL-10 antibodies. It is, however, still a plausible theory that cytokine autoantibodies might be induced by microbially derived, immunogenic cytokine homologues. In this context ebvIL-10 is even more interesting than cmvIL-10, as the similarity between hIL-10 and ebvIL-10 is very high (Zdanov, 2004) . We tried to iodinate ebvIL-10 several times. As assessed by size chromatography and Western blotting, our iodinated ebvIL-10 appeared to be monomeric, although ebvIL-10, like hIL-10 and cmvIL-10, is known to form a homodimer (Zdanov, 2004) . None of the 33 plasma pools and 200 individual blood-donor plasmas contained antibodies that bound to the monomeric ebvIL-10 tracer (data not shown). We expect that putative antiebvIL-10 antibodies will be directed against homodimeric ebvIL-10 and, as such, will not bind to monomeric ebvIL-10 ( Kanegane et al., 1997; Menetrier-Caux et al., 1996; Tanner et al., 1997) .
The presented data suggest that recombinant cmvIL-10 does not induce hIL-10. However, the effects of cmvIL-10 in the context of an ongoing virus infection have to be Plasma from six individual anti-cmvIL-10 antibody-positive blood donors treated with or without a 500-fold molar excess of unlabelled recombinant hIL-10, ebvIL-10 or cmvIL-10. Binding was assessed by using protein-G affinity chromatography. Measurements were performed in triplicate, and data are presented as means (±SD) from three separate experiments.
Anti-cmvIL-10 antibodies investigated further. Equivalent levels of hIL-10 in plasma of seropositive and seronegative donors do not rule out an autocrine induction of hIL-10 in vivo. Locally produced cmvIL-10 could feedback on cells in an autocrine manner and these effects are likely to be diluted out in peripheral plasma. Additionally, such effects may differ between latent and lytic infection.
The widespread prevalence of blood donors with relatively high levels of anti-cmvIL-10 antibodies indicates that IgG pools or plasma pools from normal donors will include clinically relevant levels of neutralizing anti-cmvIL-10 antibodies. Whether these antibodies might play a role in transfusion reactions or influence a chronic CMV infection in the recipient is speculative. Nonetheless, their existence signifies that cmvIL-10 is actually produced in CMVinfected individuals at levels that trigger a substantial specific and neutralizing humoral immune response, and that anti-cmvIL-10 antibodies represent a highly specific counter reaction of the immune system. Future studies should elucidate to what extent anti-cmvIL-10 antibodies, as well as antibodies against other CMV-encoded soluble immune modifiers, affect immunity against CMV and whether they are potential vaccine candidates.
METHODS
Recombinant IL-10 homologues. Recombinant human-cmvIL-10: a DNA sequence encoding the mature human cmvIL-10 was expressed in Escherichia coli (Lockridge et al., 2000) . Based on Nterminal sequencing, recombinant cmvIL-10 has Ala26 at the amino terminus. The 151 aa residue recombinant human-cmvIL-10 has a predicted molecular mass of approximately 17.6 kDa. The purity was determined, by SDS-PAGE and visualization by silver stain (Pierce silver stain kit; Thermo Scientific), to be .97 % (R&D Systems). Recombinant hIL-10 was derived from Sf21 insect cells (R&D Systems) and ebvIL-10 was derived from E. coli (R&D Systems). Polyclonal anti-cmvIL-10 antibodies were produced in goats immunized with E. coli-derived recombinant cmvIL-10 (Viral HCMV IL-10 affinity purified polyclonal antibody, Goat IgG; R&D Systems).
Iodination and purification of iodinated recombinant cmvIL-10.
Recombinant cmvIL-10 was labelled with 125 I using the chloramine-T method (Bendtzen et al., 2000) . The tracer was suspended in RPMI 1640 medium containing L-glutamine and HEPES (25 mM was incubated overnight at 4 6C with dilutions of plasma from six individual anti-cmvIL-10 antibody-positive blood donors. Binding was assessed by using protein-G affinity chromatography. Data are presented as the means of triplicates, and the experimental data were confirmed twice in independent experimental settings. (b) The binding avidity and binding capacity of plasma anti-cmvIL-10 antibodies. Different concentrations of 125 I-labelled recombinant cmvIL-10 were incubated overnight at 4 6C in plasma positive for anti-cmvIL-10 antibodies (donor 3, diluted ¾200). Binding was assessed by using protein-G affinity chromatography. Data are presented as the means of triplicates. The arrow indicates a Scatchard plot of the data revealing that K d 512.45 pM.
Anti-cmvIL-10 antibodies with the greatest antibody-binding abilities following the secondary separation were pooled to yield a homodimeric tracer demonstrating more than 90 % binding ability to anti-cmvIL-10 antibodies. Gel filtration revealed that .95 % of the tracer was recovered at 36 kDa. The specific activity of the tracer was estimated to be about 75 c.p.m. pg 21 .
Measurement of antibodies against cmvIL-10
Three different methods for measuring antibodies against IL-10 were used: affinity chromatography on protein G, Sephadex G-75 superfine molecular size chromatography (PD75) and secondary antibodies precipitation (SAP) assay.
Affinity chromatography. Protein-G columns contained 1000 ml protein-G Sepharose Fast Flow (Amersham Biosciences). PBS (pH 7.4) supplemented with 0.1 % Tween 20 and 0.1 % gelatin (Sigma-Aldrich) was used as running buffer. Bound material was eluted with 0.1 M glycine/HCl, pH 2.4. Fractions representing IgGbound tracer and free tracer were counted in a c counter (1272 CliniGamma LKB; Wallac). Counting error was ,8 % (the length of the counting time ensured that the 95 % confidence interval of the counting result was ±8 %).
PD75. Size chromatography columns contained 18 ml Sephadex G-75 superfine (Amersham Biosciences). Fractions representing bound and free tracer were counted in a c counter (1272 CliniGamma LKB; Wallac) with an error of ,8 % as described above.
A typical experimental setup was as follows: 90 ml of 125 I-labelled cmvIL-10 (5000-10 000 c.p.m.) was added to 10 ml of appropriately diluted goat anti-cmvhIL-10 or human plasma. After an overnight incubation at 4 uC, the samples were separated by either affinity or size ) were pre-incubated with different concentrations of cmvIL-10 in 10 % of the above-mentioned plasma pools and then stimulated with LPS for 8 h at 37 6C. The supernatant levels of IL-1b and TNFa were measured by ELISA (in triplicate). LPS stimulated blood mononuclear cells without cmvIL-10 (in both anti-cmvIL-10 antibodypositive or -negative plasma), resulted in approximately 2500 pg ml "1 IL-1b and 22 000 pg ml "1 TNFa (data not shown). Data are presented as the means and SD of three independent assays. (c) Blood mononuclear cells (1.0¾10 6 cells ml SAP assay. Pilot experiments were conducted to determine the optimal precipitating concentrations of polyclonal rabbit anti-human IgG (A0424), polyclonal rabbit anti-human k light chains, (A0192) and polyclonal rabbit anti-human l light chains (A0194), all of which were obtained from Dako.
A typical experimental setup for SAP assay was as follows: to 30 ml 125 I-labelled cmvIL-10 (5000-10 000 c.p.m.) were added 10 ml of appropriately diluted human plasma containing natural antibodies against cmvIL-10. After overnight incubation at 4 uC, 150 ml A0424, A0192 or A0194 was added and the samples were incubated for 1 h at 4 uC with gentle stirring. Eight hundred microlitres of ice-cold PBS buffer containing 0.1 % Tween-20 was then added and the samples were centrifuged for 20 min (3000 g at 4 uC). Quantification of the amounts of labelled tracer in the pellet (antibody bound cmvIL-10) and supernatant (free cmvIL-10) were carried out as described above.
Assays using peripheral blood mononuclear cells (PBMC).
PBMC were isolated from healthy O rhesus D-positive blood donors by Leucosep density-gradient centrifugation (Greiner Bio-One). Blood mononuclear cells were suspended in RPMI 1640 medium containing 25 mM HEPES (Gibco) and supplemented with 0.8 mM L-glutamine and 2.5 mg gentamicin ml 21 (Sigma-Aldrich).
Receptor binding assay.
125
I-labelled cmvIL-10 was incubated with 2-5610 6 PBMC ml 21 overnight at 4 uC with stirring in plasma that was positive or negative for antibodies against cmvIL-10. This was performed with or without a molar excess of non-labelled cmvIL-10 or hIL-10. After incubation, the cell cultures were centrifuged at 4000 g for 20 min, after which the amounts of labelled tracer in the pellet (tracer bound to cells) and supernatant (free tracer) were measured.
Bioassay with PBMC. The biological activity of antibodies against cmvIL-10 was assessed by the antibodies' ability to neutralize the effects of recombinant cmvIL-10, specifically the ability to: (1) abrogate the inhibitory activity of cmvIL-10 in reducing the LPSinduced IL-1b and TNF-a and (2) abrogate the phosphorylation of STAT3 induced by cmvIL-10.
(1) Blood mononuclear cells (2.0610 6 cells ml
21
) were cultured in the presence or absence of 20 ng LPS ml 21 (Sigma-Aldrich) without or with different concentrations of recombinant cmvIL-10. All samples were supplemented with 10 % heat-inactivated human plasma (adjudged negative or positive for anti-cmvIL-10 antibodies). Both anti-cmvIL-10 and anti-hIL-10 antibodies were unaffected by heat inactivation. After 8 h at 37 uC, culture supernatants (1000 ml) were harvested by centrifugation (2000 g for 15 min) and analysed for human IL-1b and TNFa by means of ELISA (R&D Systems).
(2) Blood mononuclear cells (1.0610 6 cells ml 21 ) were stimulated with 10 ng ml 21 of recombinant hIL-10 or cmvIL-10 for 20 min at 37 uC in the presence 10 % heat-inactivated plasma [adjudged either highly positive (B/T ¢85 %) or negative for anti-cmvIL-10 antibodies]. The concentration of cmvIL-10 was based on a bioassay using 0, 1, 10, 20, 50 and 100 ng cmvIL-10 ml 21 , and this study illustrated that 10 ng ml 21 was the optimal experimental concentration. The incubation time was 20 min, based on a time-dependent study where blood mononuclear cells were stimulated for 10, 20, 30 and 60 min (inspired by Spencer et al., 2008, data not shown) . Cell cultures were then centrifuged for 15 min at 2000 g, after which phosphorylated STAT3 and total STAT3 were determined in cell lysates by Western blotting.
Phosphorylation of STAT3 assessed by Western blotting. The cell lysis buffer contained 20 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 % Triton X-100 and 1 mM Na 3 VO 4 , and was supplemented with protease inhibitor cocktail tablets (Roche diagnostics) as well as phosphatase inhibitor cocktails 1 and 2 according to the manufacturer's instructions (Sigma-Aldrich). Total protein was determined using a Bio-Rad DC kit (Bio-Rad). Equal amounts of protein were separated by SDS-PAGE, and proteins were transferred to PVDF membranes (Amersham Pharmacia Biotech). Membranes were incubated overnight with anti-phospho-STAT3 (Tyr705) (Cell Signalling Technology) or anti-STAT3 (Santa Cruz Biotechnology). Peroxidase-conjugated secondary antibodies were obtained from Dako. All antibodies were diluted in 5 % TOP-Blok (Biochemika, Sigma-Aldrich); the primary antibodies were diluted 1 : 1000 and the secondary antibodies 1 : 20 000. Total STAT3 served as the loading control (Spencer et al., 2008) . Proteins were visualized using Super Signal West Femto (Pierce) and quantified using MOLECULAR ANALYST software (software and charge-coupled device camera from Bio-Rad).
Screening of plasma from blood donors. Plasma samples from normal blood donors were collected from the Blood Bank at the National University Hospital (Rigshospitalet, Denmark). Plasma was anti-coagulated with citrate (135 mM) and plasma samples were stored at -20 uC. All donors fulfilled the criteria for blood donation stated by the EU Directives and the Danish Society for Clinical Immunology. The detection limit for an antibody-positive sample was arbitrarily set to B/T¢10 %. This limiting value was chosen because it represented a substantial number of c.p.m. that could be subjected to displacement using an excess of unlabelled IL-10. Highly positive plasmas were defined as those binding .75 %. Two pools of plasma were generated and used throughout this study. One pool consisted of equal amounts of plasma from six donors who were HCMVseropositive and highly positive for anti-cmvIL-10 antibodies. Another pool consisted of ten donors who were HCMV-seronegative and negative for anti-cmvIL-10 antibodies. 
Anti-cmvIL-10 antibodies
Measurement of IL-10 in plasma. IL-10 was determined by electrochemiluminescence detection technology in a Multi-Spot 96-well small spot plate cytokine assay (Meso Scale Discovery). IL-10 was measured in duplicates and the mean calculated. The detection limit was 1.2 pg ml 21 .
CMV status. Plasma samples from blood donors were analysed for anti-CMV IgG antibodies using a Vitros immunodiagnostic CMV assay (Johnson and Johnson Nordic), according to the manufacturer's instructions. This assay is based on purified extract of viral lysate without any spike of recombinant proteins.
Ethics. This study was approved by our institution and the local ethical authority under code number KF 01-110/98.
